Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update May 13, 2021 16:01 ET | Source: Brickell Biotech, Inc. Brickell Biotech, Inc. Boulder, Colorado, UNITED STATES Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study - - - - - - Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021 BOULDER, Colo., May 13, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.